Eli Lilly and (LLY) Receives Daily News Sentiment Score of 0.13
News articles about Eli Lilly and (NYSE:LLY) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eli Lilly and earned a news impact score of 0.13 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.7740040699496 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Do What Insiders Does: Take-Two Interactive Software, Inc. (TTWO), Eli Lilly and Company (LLY) – Market Movers (financialqz.com)
- FDA approves diabetes drug that also helps with weight loss – 10TV (10tv.com)
- Eli Lilly & Co. (LLY) Initiates Clinical Trial to Evaluate Functionality, Safety of its Automated Insulin Delivery … – StreetInsider.com (streetinsider.com)
- Viagra goes generic: Pfizer to launch own little white pill (marketbeat.com)
- Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in … (businesswire.com)
Several equities analysts have recently commented on LLY shares. Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Cowen reaffirmed a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Jefferies Group reaffirmed a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a research report on Monday, September 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research report on Thursday, August 31st. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $90.25.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter last year, the business earned $0.88 earnings per share. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. sell-side analysts anticipate that Eli Lilly and will post 4.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.42%. Eli Lilly and’s payout ratio is currently 98.58%.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The disclosure for this sale can be found here. Insiders sold 628,588 shares of company stock worth $53,399,536 in the last 90 days. 0.20% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Eli Lilly and (LLY) Receives Daily News Sentiment Score of 0.13” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/06/eli-lilly-and-lly-receives-daily-news-sentiment-score-of-0-13.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.